In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Over the years, there has been an increasing demand for an effective and cost-efficient drug discovery process. The study of ...

NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...